Skip to Main Content

Author Details

Samuel S Freeman
St Vincent's Hospital Melbourne
2006
40
28
PMIDPaper TitleJournal TitlePublished Year
36853705Protocol for bulk RNA sequencing of enriched human neutrophils from whole blood and estimation of sample purity.STAR Protoc2023
38096321Applications of natural language processing at emergency department triage: A narrative review.PLoS One2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37066412Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response.bioRxiv2023
36858677Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.Lancet Haematol2023
36853705Protocol for bulk RNA sequencing of enriched human neutrophils from whole blood and estimation of sample purity.STAR Protoc2023
38096321Applications of natural language processing at emergency department triage: A narrative review.PLoS One2023
37024582Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.Nat Genet2023
37066412Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response.bioRxiv2023
36858677Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.Lancet Haematol2023
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35508657Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanoma.Nature2022
36151395In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.Nat Immunol2022
36208629Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients.Cell Rep Med2022
35243413Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.Cell Rep Med2022
35084050Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.Prostate2022
35508657Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanoma.Nature2022
36208629Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients.Cell Rep Med2022
36151395In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.Nat Immunol2022
35243413Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.Cell Rep Med2022
33203734The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.Cancer Discov2021
34016182Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.Genome Med2021
34253920Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.Nat Genet2021
33203734The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.Cancer Discov2021
33229411KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.Cancer Immunol Res2021
34016182Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.Genome Med2021
34253920Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.Nat Genet2021
33229411KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1.Cancer Immunol Res2021
32170028Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.Clin Cancer Res2020
32170028Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.Clin Cancer Res2020
32723837Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer.Clin Cancer Res2020
32938797Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect.Sci Transl Med2020
32938797Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect.Sci Transl Med2020
32723837Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer.Clin Cancer Res2020
30531871Acquired HER2 mutations in ER<sup>+</sup> metastatic breast cancer confer resistance to estrogen receptor-directed therapies.Nat Genet2019
31784532Genomic and immune profiling of pre-invasive lung adenocarcinoma.Nat Commun2019
30531871Acquired HER2 mutations in ER<sup>+</sup> metastatic breast cancer confer resistance to estrogen receptor-directed therapies.Nat Genet2019
30564890Identification and characterization of an alternative cancer-derived PD-L1 splice variant.Cancer Immunol Immunother2019
30633907Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2019
30851984The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.Eur Urol2019
31784532Genomic and immune profiling of pre-invasive lung adenocarcinoma.Nat Commun2019
30851984The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.Eur Urol2019
30633907Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2019
30564890Identification and characterization of an alternative cancer-derived PD-L1 splice variant.Cancer Immunol Immunother2019
28978556Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.Cancer Discov2018
28978556Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.Cancer Discov2018
30388456Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.Cell2018
30385733Tumor fraction in cell-free DNA as a biomarker in prostate cancer.JCI Insight2018
29909985Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.Cell2018
29703982Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.Nat Commun2018
  • 1 - 50 of 80

Recommended Authors

Jacob Pfeil
UC Santa Cruz Genomics Institute
Career Start Year 2015
Number of shared co-authors 2
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 3
Reyka G Jayasinghe
Washington University in St Louis
Career Start Year 2015
Number of shared co-authors 2
Scott D Brown
BC Cancer Research Institute
Career Start Year 2014
Number of shared co-authors 6
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 2
Jiguang Wang
The Hong Kong University of Science and Technology
Career Start Year 2012
Number of shared co-authors 5
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 4
Elana J Fertig
Johns Hopkins University School of Medicine
Career Start Year 2010
Number of shared co-authors 6
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Benjamin G Vincent
UNC School of Medicine, The University of North Carolina at Chapel Hill
Career Start Year 2008
Number of shared co-authors 9
Oscar Krijgsman
The Netherlands Cancer Institute
Career Start Year 2008
Number of shared co-authors 1
Ken Chen
University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 20
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 4
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 10
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 1
Catrina Fronick
McDonnell Genome Institute, Washington University in St. Louis School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Jason Walker
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 3
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 6
Fengshen Kuo
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 1
Malachi Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 3
Amy G Robertson
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 38
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 25
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 45
Vladimir Makarov
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 8
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 11
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year 1999
Number of shared co-authors 6
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 21
Timothy A Chan
Cleveland Clinic.
Career Start Year 1994
Number of shared co-authors 38
Aaron M Newman
Stanford University
Career Start Year 1994
Number of shared co-authors 7

Collaborators

Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 17
Matthew Meyerson
Broad Institute
Co-authored papers 13
Nir Hacohen
Broad Institute of MIT and Harvard
Co-authored papers 10
Chandra Sekhar Pedamallu
Broad Institute
Co-authored papers 7
Akinyemi I Ojesina
University of Alabama at Birmingham
Co-authored papers 6
Nancy U Lin
Co-authored papers 5
Nikhil Wagle
Dana-Farber Cancer Institute
Co-authored papers 5
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 5
Donna Neuberg
Co-authored papers 5
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 5
Ignaty Leshchiner
Broad Institute of Massachusetts Institute of Technology and Harvard
Co-authored papers 4
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 4
Alexandra-Chloé Villani
Co-authored papers 4
Todd R Golub
Broad Institute of MIT and Harvard
Co-authored papers 4
Keren Yizhak
Co-authored papers 4
Chip Stewart
Broad Institute of MIT and Harvard
Co-authored papers 4
Jaegil Kim
Co-authored papers 4
Catherine J Wu
Co-authored papers 3
Aaron R Thorner
Co-authored papers 3
Elena Ivanova
Dana-Farber Cancer Institute
Co-authored papers 3
Matthew Ducar
Co-authored papers 3
Mara Rosenberg
Broad Institute of MIT and Harvard
Co-authored papers 3
Michael S Lawrence
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 3
Joonil Jung
Broad Institute of MIT and Harvard
Co-authored papers 3
Jens G Lohr
Co-authored papers 3
Fujiko Duke
Co-authored papers 3
Anat Stemmer-Rachamimov
Massachusetts General Hospital
Co-authored papers 3
Stacey Gabriel
Broad Institute of MIT and Harvard
Co-authored papers 3
Sara M Tolaney
Dana-Farber Cancer Institute
Co-authored papers 3
Release 1.2